Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.92)
# 120
Out of 5,182 analysts
51
Total ratings
74%
Success rate
56.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterates: Buy | $18 | $5.46 | +229.67% | 2 | Apr 10, 2026 | |
| NBP NovaBridge Biosciences | Reiterates: Buy | $9 | $2.39 | +276.57% | 3 | Apr 8, 2026 | |
| CGON CG Oncology | Maintains: Buy | $80 → $100 | $65.55 | +52.56% | 6 | Apr 7, 2026 | |
| AURA Aura Biosciences | Reiterates: Buy | $22 | $6.96 | +216.09% | 2 | Mar 30, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Neutral | $60 → $53 | $52.94 | +0.11% | 3 | Mar 25, 2026 | |
| STRO Sutro Biopharma | Upgrades: Buy | $10 → $28 | $34.87 | -19.70% | 2 | Mar 24, 2026 | |
| ERAS Erasca | Maintains: Buy | $15 → $20 | $9.90 | +102.02% | 3 | Mar 13, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $5.17 | +151.45% | 1 | Mar 10, 2026 | |
| ENGN enGene Therapeutics | Reiterates: Buy | $25 | $6.96 | +259.20% | 3 | Mar 9, 2026 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $58 | $46.73 | +24.12% | 3 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $6.96 | +115.52% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $23.71 | +68.71% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.06 | +354.55% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $0.74 | +440.54% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.26 | +455.56% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $21.11 | +89.48% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $9.82 | +307.33% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $6.20 | +270.97% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $54.48 | +92.73% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $11.37 | +75.90% | 1 | Aug 8, 2025 |
Verastem
Apr 10, 2026
Reiterates: Buy
Price Target: $18
Current: $5.46
Upside: +229.67%
NovaBridge Biosciences
Apr 8, 2026
Reiterates: Buy
Price Target: $9
Current: $2.39
Upside: +276.57%
CG Oncology
Apr 7, 2026
Maintains: Buy
Price Target: $80 → $100
Current: $65.55
Upside: +52.56%
Aura Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $22
Current: $6.96
Upside: +216.09%
Terns Pharmaceuticals
Mar 25, 2026
Downgrades: Neutral
Price Target: $60 → $53
Current: $52.94
Upside: +0.11%
Sutro Biopharma
Mar 24, 2026
Upgrades: Buy
Price Target: $10 → $28
Current: $34.87
Upside: -19.70%
Erasca
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $9.90
Upside: +102.02%
Foghorn Therapeutics
Mar 10, 2026
Reiterates: Buy
Price Target: $13
Current: $5.17
Upside: +151.45%
enGene Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $25
Current: $6.96
Upside: +259.20%
Scholar Rock Holding
Mar 3, 2026
Reiterates: Buy
Price Target: $58
Current: $46.73
Upside: +24.12%
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $6.96
Upside: +115.52%
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $23.71
Upside: +68.71%
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $5.06
Upside: +354.55%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.74
Upside: +440.54%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.26
Upside: +455.56%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $21.11
Upside: +89.48%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $9.82
Upside: +307.33%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $6.20
Upside: +270.97%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $54.48
Upside: +92.73%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $11.37
Upside: +75.90%